Marina Biotech Inc. is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics. The company’s innovative therapeutics utilize multiple mechanisms of action, including RNA interference and messenger RNA translational blocking.

The company reported today that China’s State Intellectual Property Office has issued a Notification of Granting Patent Rights for PRC 200680047851. This patent covers pharmaceutical formulations for intranasal delivery of insulin, and uses of the formulation to treat diseases associated with inappropriate insulin levels.

The president of CEO of Marina Biotech, J. Michael French, said, “We believe that the intranasal assets from our predecessor company, Nastech Pharmaceutical, have considerable value. Our intranasal insulin program has the potential to serve patients with diabetes, and holds additional promise in the treatment of CNS (central nervous system) diseases such as Alzheimer’s.”

Combined with the current patent protection in Europe, this patent grant in China further expands and strengthens the company’s insulin patent portfolio. For additional information about Marina Biotech and its products, please visit the company’s website at www.marinabio.com

Let us hear your thoughts below: